Biocytogen Announces Dr. Zhaoxue (Luke) Yu as Global Head of Preclinical Pharmacology
On March 31st, Biocytogen announced Dr. Zhaoxue (Luke) Yu as our Global Head of Preclinical Pharmacology. As our global preclinical pharmacology team leader, Dr. Yu is dedicated to furthering Biocytogen’s innovative antibody discovery platform and serving as our liaison person for strategic partnerships between Biocytogen and external collaborators.
Dr. Yu brings more than 15 years of research and technical leadership experience in drug discovery and model design for immune/autoimmune rare genetic diseases, neurological diseases, tumors and metabolic diseases across various therapeutic modalities including antibodies, biologics, small molecules, mRNAs, and AAVs. Prior to Biocytogen, Dr. Yu served as a pharmacology technical leader at Gemini Pharmaceuticals, Achillion Pharmaceuticals, and Alexion Pharmaceuticals. Dr. Yu has been a major contributor to multiple drug development programs from preclinical to clinical stages, some of which have subsequently obtained success approvals by the FDA.
Dr. Yu received his Ph.D in Neurobiology and M.D. in China. He has held postdoctoral research positions at institutions including Emory University, Yale University, and Boston Children’s Hospital. Dr. Yu is an established author of multiple publications in peer-reviewed journals and patents, in addition to being a speaker at several international conferences and seminars.